Antiphospholipid syndrome – what’s new?

Elżbieta Szczepaniak; Agnieszka Osmola; Janusz Prokop

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2004
vol. 21

Send email

Copy url:

abstract:

Antiphospholipid syndrome – what’s new?

Elżbieta Szczepaniak

,

Agnieszka Osmola

,

Janusz Prokop

PDiA 2004; XXI, 6: 286–290

Online publish date: 2004/12/20

View full text Get citation

Antiphospholipid syndrome is characterized by the presence of heterogenous group of antibodies for which cofactors are β2 glicoprotein-1 (β2 GP I), protrombin, proteins S and C, thrombomodulin and anexin. Clinical picture strictly depends on diameter and type of vessels thrombosis (capillary vessels, veins, arteries) of skin, internal organs or brain. Characteristic symptoms include recurrently obstetrics outcome and thrombocytopenia. The role of phospholipids binding proteins – β2-GPI as autoantigens in pathogenesis of antiphospholipid syndrome is recently often discussed.

keywords:

Antiphospholipid syndrome – what’s new?

Elżbieta Szczepaniak , Agnieszka Osmola , Janusz Prokop

antiphospholipid syndrome, antiphospholipid antibodies, lupus anticoagulant, anticardiolipin antibodies

Elżbieta Szczepaniak

,

Agnieszka Osmola

,

Janusz Prokop